When Brukinsa (zanubrutinib) stops working for mantle cell lymphoma (MCL), there are still several treatment paths worth discussing with your oncologist. Here's a summary of options that may be considered: Targeted Therapies
- Acalabrutinib (Calquence) — another BTK inhibitor
- Pirtobrutinib (Jaypirca) — a newer BTK Show Full Answer
When Brukinsa (zanubrutinib) stops working for mantle cell lymphoma (MCL), there are still several treatment paths worth discussing with your oncologist. Here's a summary of options that may be considered: Targeted Therapies:
- Acalabrutinib (Calquence) — another BTK inhibitor
- Pirtobrutinib (Jaypirca) — a newer BTK inhibitor that may work even after other BTK inhibitors fail
- Venetoclax (Venclexta) — used off-label for MCL
- Bortezomib (Velcade) — blocks proteins involved in MCL growth
- Lenalidomide (Revlimid) — another targeted option Immunotherapy Combinations:
- Lenalidomide combined with rituximab is one option that has shown benefit in relapsed or refractory MCL. Chemotherapy:
- Chemotherapy regimens not previously used, such as bendamustine (Treanda), hyper-CVAD, or R-CHOP combinations, may be considered depending on prior treatment history. Stem Cell Transplant:
- A high-dose chemotherapy regimen followed by a bone marrow (stem cell) transplant may be an option, particularly if the lymphoma responds well to chemotherapy first. Clinical Trials:
- Since treatment options for MCL can be limited, clinical trials exploring newer therapies are worth asking your oncologist about. They may offer access to cutting-edge treatments not yet widely available.
It's really important to have an open conversation with your oncologist about which of these options best fits your specific situation, health history, and goals. Every case is different, and they can help weigh the benefits and risks for you personally.
June 22
Join
Your Privacy Choices
